Liver Cancer Clinical Trials 2022
Liver Cancer studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect liver cancer clinical trial in 2022.
Condition
Liver Cancer
Location
Distance
10 miles
50 miles
Any
Age
Search
Clinical Trials
Liver Cancer Clinical Trials 2022
Phase-Based Estimates
1
Effectiveness
1
Safety
Adhesion Barrier
for Tissue Adhesions
Calgary, Canada
18+
All Sexes
Waitlist Available
Metastatic
Calgary, Canada
18+
All Sexes
This study is evaluating whether a topical anti-adhesion barrier can reduce adhesions at the time of repeat hepatic surgery.
Phase-Based Estimates
1
Effectiveness
1
Safety
ET140203 T Cells
for Cancer
Boston, MA
< 65
All Sexes
Phase 1 & 2
Recruiting
Class I
Boston, MA
< 65
All Sexes
This study is evaluating whether a type of white blood cell may help treat children with cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
TSR-022 And TSR-042
for Liver Neoplasms
Honolulu, HI
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Honolulu, HI
18+
All Sexes
This study is evaluating whether a combination of two antibodies may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Hypovolemic Phlebotomy
for Blood Loss, Surgical
Montréal, Canada
18+
All Sexes
Recruiting
Montréal, Canada
18+
All Sexes
This study is evaluating whether a blood donation can reduce blood loss during liver surgery.
Phase-Based Estimates
1
Effectiveness
2
Safety
Cisplatin
for Carcinoma, Hepatocellular
Royal Oak, MI
< 65
All Sexes
Phase 2 & 3
Recruiting
High Risk
Royal Oak, MI
< 65
All Sexes
This study is evaluating whether cisplatin and combination chemotherapy may help treat children and young adults with hepatoblastoma or hepatocellular carcinoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
CDX-1140
for Waldenstrom Macroglobulinemia
Portland, OR
18+
All Sexes
Phase 1
Waitlist Available
Locally Advanced
Portland, OR
18+
All Sexes
This study is evaluating whether a drug which targets a protein on the surface of white blood cells may help treat certain types of cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Trans-arterial Tirapazamine Embolization
for Liver Neoplasms
Orange, CA
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Orange, CA
18+
All Sexes
This study is evaluating whether a new treatment for liver cancer may be effective.
Phase-Based Estimates
1
Effectiveness
2
Safety
Sorafenib (SOR)
for Carcinoma, Hepatocellular
San Antonio, TX
18+
All Sexes
Phase 2
Recruiting
Grade III
San Antonio, TX
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat advanced liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
GAP T Cells
for Liver Neoplasms
Houston, TX
< 65
All Sexes
Phase 1
Waitlist Available
1 Prior Treatment
Houston, TX
< 65
All Sexes
This study enrolls patients who have GPC3-positive solid tumors currently. Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called GAP T cells, a new experimental treatment. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. In preclinical studies, the investigators made several genes called a chimeric antigen receptor (CAR), from an antibody called GC33 that recognizes glypican-3, a proteoglycan found on solid tumors including pediatric liver cancers (GPC3-CAR). This study will test T cells genetically engineered with a GPC3-CAR (GAP T cells) in patients with GPC3-positive solid tumors (currently only enrolling liver tumors). The GAP T cells are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to find the biggest dose of GAP T cells that is safe, to see how long they last in the body, to learn what the side effects are and to see if the GAP T cells will help people with GPC3-positive solid tumors. This study enrolls patients who have GPC3-positive solid tumors (currently only enrolling liver tumors).
Phase-Based Estimates
1
Effectiveness
1
Safety
Technetium Tc-99m Sulfur Colloid
for Carcinoma, Hepatocellular
Seattle, WA
18+
All Sexes
Recruiting
Metastatic
Seattle, WA
18+
All Sexes
This study is evaluating whether a type of imaging test may help doctors plan better treatment for patients with liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Surefire
for Liver Neoplasms
Boston, MA
18+
All Sexes
Recruiting
Locally Advanced
Boston, MA
18+
All Sexes
This research study is studying the Surefire Infusion System ("Surefire") for increasing delivery of chemotherapeutic agents delivered trans-arterially to intermediate stage Hepatocellular Carcinoma ("HCC") (Barcelona Clinic Liver Cancer (BCLC) class B; locally advanced, liver restricted disease patients. The names of the study interventions involved in this study are: -Trans-arterial chemoembolization ("TACE") with or without the utilization of Surefire
Phase-Based Estimates
1
Effectiveness
2
Safety
LC Bead LUMI
for Carcinoma, Hepatocellular
Bethesda, MD
18+
All Sexes
Phase 2
Waitlist Available
Metastatic
Bethesda, MD
18+
All Sexes
This study is evaluating whether a new embolization material called LC LUMI beads can shrink tumors and be seen on x-ray and CT images.
Phase-Based Estimates
1
Effectiveness
1
Safety
Tas-102
for Liver Neoplasms
San Francisco, CA
18+
All Sexes
Phase 1
Waitlist Available
Metastatic
San Francisco, CA
18+
All Sexes
This study is evaluating whether a combination of a drug and a radiation therapy is safe for people with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Outreach With Patient Education And Patient Navigation Services
for Carcinoma, Hepatocellular
Dallas, TX
18+
All Sexes
Waitlist Available
Dallas, TX
18+
All Sexes
This study is evaluating whether a mailed outreach strategy can increase HCC surveillance among patients with cirrhosis.
Phase-Based Estimates
1
Effectiveness
1
Safety
Magnetic Resonance High Intensity Focused Ultrasound
for Neuroblastoma
Washington, United States
< 65
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Washington, United States
< 65
All Sexes
This study is evaluating whether a combination of a drug and a focused ultrasound may be effective for treating children with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Talimogene Laherparepvec
for Liver Neoplasms
Scottsdale, AZ
18+
All Sexes
Phase 1 & 2
Waitlist Available
Locally Advanced
Scottsdale, AZ
18+
All Sexes
This study is evaluating whether injecting a virus into a tumor in the liver may help treat cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Ropidoxuridine
for Gastrointestinal Neoplasms
Providence, RI
18+
All Sexes
Phase 1
Waitlist Available
Locally Advanced
Providence, RI
18+
All Sexes
This study is evaluating whether a drug called ropidoxuridine can make cancer cells more sensitive to radiation therapy.
Phase-Based Estimates
1
Effectiveness
1
Safety
Tirapazamine
for Neuroendocrine Tumors
San Francisco, CA
18+
All Sexes
Phase 1 & 2
Waitlist Available
Locally Advanced
San Francisco, CA
18+
All Sexes
This study is evaluating whether tirapazamine is safe and effective when combined with embolization in liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Vitamin D3
for Cancer of Colon
Boston, MA
18+
All Sexes
Phase < 1
Recruiting
High Risk
Boston, MA
18+
All Sexes
This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cancer cell death. Vitamin D has been used in other research studies and information from those other research studies suggests that Vitamin D may help in the treatment of colon cancer. Participants will receive either high-dose vitamin D or standard-dose vitamin D. The study drug will be given 14-28 days prior to your surgery. The number of days will depend on when the surgery is scheduled.
Phase-Based Estimates
2
Effectiveness
3
Safety
Stereotactic Body Radiation Therapy
for Carcinoma, Hepatocellular
Richmond, VA
18+
All Sexes
Phase 3
Waitlist Available
Locally Advanced
Richmond, VA
18+
All Sexes
This study is evaluating whether a combination of sorafenib and stereotactic body radiation therapy is more effective than sorafenib alone in treating patients with liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Iodinated Contrast Dye
for Liver Neoplasms
Philadelphia, PA
18+
All Sexes
Waitlist Available
Class V
Philadelphia, PA
18+
All Sexes
This study is evaluating whether contrast-enhanced CT scan and contrast-enhanced MRI can help find liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
HAI Plus Systemic Chemotherapy
for Liver Neoplasms
Commack, NY
18+
All Sexes
Phase 2
Waitlist Available
Metastatic
Commack, NY
18+
All Sexes
This study is evaluating whether the addition of bevacizumab to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus 5-fluor
Phase-Based Estimates
1
Effectiveness
2
Safety
Bevacizumab
for Hepatocellular Carcinoma
Duarte, CA
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Duarte, CA
18+
All Sexes
This is a randomized Phase 2 trial designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
Phase-Based Estimates
1
Effectiveness
2
Safety
Lenvatinib
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 2
Waitlist Available
Houston, TX
18+
All Sexes
We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, and exploratory data will be compared to a matched, retrospective cohort.
Phase-Based Estimates
1
Effectiveness
2
Safety
Atezolizumab
for Stage IV Hepatocellular Carcinoma AJCC v8
Scottsdale, AZ
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Scottsdale, AZ
18+
All Sexes
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
DB-1303
for HER2-positive Advanced Solid Tumor
Oklahoma City, OK
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Oklahoma City, OK
18+
All Sexes
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303 in subjects with advanced solid tumors that express HER2.
Phase-Based Estimates
1
Effectiveness
1
Safety
Atezolizumab
for Carcinoma
Tampa, FL
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Tampa, FL
18+
All Sexes
This study is evaluating whether a drug called Selinexor can be used to treat advanced Hepatocellular Carcinoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Microsieve
for Cancer of Pancreas
Tampa, FL
18+
All Sexes
Waitlist Available
Tampa, FL
18+
All Sexes
This study is evaluating whether the use of a blood thinner or saline solution in the needle being used to sample your abdominal tumor will affect the amount and quality of tissue obtained by EUS-FNB.
Phase-Based Estimates
1
Effectiveness
1
Safety
CAR-T Cell
for Carcinoma, Hepatocellular
Bethesda, MD
18+
All Sexes
Phase 1
Recruiting
Grade I
Bethesda, MD
18+
All Sexes
This study is evaluating whether a new treatment for liver cancer is safe.
Phase-Based Estimates
1
Effectiveness
2
Safety
Capecitabine Tablets + Temozolomide Tablets + SIR-Spheres
for Neuroendocrine Tumors
Philadelphia, PA
18+
All Sexes
Phase 2
Recruiting
Grade I
Philadelphia, PA
18+
All Sexes
This study is evaluating whether a combination of capecitabine and temozolomide is safe and effective in patients with grade 2 neuroendocrine tumors.
Phase-Based Estimates
1
Effectiveness
1
Safety
Anti-CTLA4 Monoclonal Antibody BMS-986218
for Cancer
Houston, TX
18+
All Sexes
Phase 1 & 2
Recruiting
Metastatic
Houston, TX
18+
All Sexes
This study is evaluating the side effects of a combination of anti-CTLA4-NF mAb (BMS986218), nivolumab, and stereotactic body radiation therapy in treating patients with solid malignancies that has spread to other places in the body (metast
Phase-Based Estimates
1
Effectiveness
2
Safety
Atezolizumab
for Carcinoma, Non-Small-Cell Lung
Toronto, Canada
18+
All Sexes
Phase 2
Recruiting
Grade I
Toronto, Canada
18+
All Sexes
This study is evaluating whether a drug called atezolizumab is effective for people with inoperable liver cancer or non-small lung cancer that has spread to the liver.
Phase-Based Estimates
1
Effectiveness
1
Safety
RO7247669
for Liver Neoplasms
New Haven, CT
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
New Haven, CT
18+
All Sexes
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Phase-Based Estimates
1
Effectiveness
1
Safety
Pembrolizumab
for Carcinoma
Houston, TX
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether a new drug may help treat cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
ONCR-177
for Liver Neoplasms
Nashville, TN
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Nashville, TN
18+
All Sexes
This study is evaluating whether a virus which infects cancer cells may help treat cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
TACE
for Liver Neoplasms
La Jolla, CA
18+
All Sexes
Phase 3
Waitlist Available
La Jolla, CA
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Pembrolizumab
for Carcinoma
Cincinnati, OH
< 65
All Sexes
Phase 2
Recruiting
Grade I
Cincinnati, OH
< 65
All Sexes
This study is evaluating whether an immunotherapy drug may help treat liver cancer in children.
Phase-Based Estimates
1
Effectiveness
1
Safety
Yttrium-90 RadioEmbolization
for Neoplasm Metastasis
Iowa City, IA
18+
All Sexes
Phase 1 & 2
Recruiting
Metastatic
Iowa City, IA
18+
All Sexes
This study is evaluating whether a combination of immunotherapy and radiation therapy may be effective for individuals with liver-predominant colorectal cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Magnetic Resonance Elastography
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Recruiting
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether a new imaging technique may help doctors determine if a treatment is working for patients with liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Ipilimumab
for Cancer
Houston, TX
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether a combination of immunotherapy and radiation therapy may be effective in treating patients with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Pneumococcal 13-valent Conjugate Vaccine
for Carcinoma, Hepatocellular
Rochester, MN
18+
All Sexes
Phase < 1
Recruiting
Rochester, MN
18+
All Sexes
This study is evaluating whether autologous dendritic cells and Prevnar are safe for patients with liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Hepatic Artery Infusion Pump
for Cancer of Pancreas
Grand Rapids, MI
18+
All Sexes
Phase 2
Recruiting
Metastatic
Grand Rapids, MI
18+
All Sexes
This study is evaluating whether a chemotherapy drug may help reduce the size of liver tumors in individuals with pancreatic cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Yttrium Y 90 Glass Microspheres
for Carcinoma, Hepatocellular
Chicago, IL
18+
All Sexes
Phase < 1
Waitlist Available
Chicago, IL
18+
All Sexes
This study is evaluating whether a combination of nivolumab and yttrium-90 may be more effective than either treatment alone.
Phase-Based Estimates
1
Effectiveness
1
Safety
Stereotactic Body Radiation Therapy
for Carcinoma, Hepatocellular
Portland, OR
18+
All Sexes
Recruiting
Locally Advanced
Portland, OR
18+
All Sexes
This study is evaluating whether stereotactic body radiation therapy is an effective treatment for liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Derazantinib
for Cholangiocarcinoma
Dallas, TX
18+
All Sexes
Phase 2
Waitlist Available
Locally Advanced
Dallas, TX
18+
All Sexes
This study is evaluating whether a drug may help treat a type of liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Perflutren Protein-Type A Microspheres
for Carcinoma, Hepatocellular
Philadelphia, PA
18+
All Sexes
Phase 2
Recruiting
Philadelphia, PA
18+
All Sexes
This study is evaluating whether a contrast agent may help improve the effectiveness of radiation therapy for liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Cetuximab
for Carcinoma, Squamous Cell
Saint Louis, MO
18+
All Sexes
Phase 1
Recruiting
Saint Louis, MO
18+
All Sexes
This study is open to adults with head and neck cancer or liver cancer. This is a study for people for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out whether combining different medicines make tumours shrink in people with head and neck cancer or liver cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 765063 and ezabenlimab may help the immune system fight cancer (checkpoint inhibitors). Cetuximab blocks growth signals and may prevent the tumour from growing. BI 836880 blocks the formation of new blood vessels that the tumour needs to grow. All participants get BI 765063 and ezabenlimab. One group gets no additional medicine. The other groups get either BI 836880, cetuximab, or chemotherapy. BI 765063, ezabenlimab, and BI 836880 are given as infusions into veins every 3 weeks. Cetuximab is given as an infusion every 1 or 2 weeks. Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors monitor the size of the tumour. The doctors also regularly check participants' health and take note of any unwanted effects.
Phase-Based Estimates
1
Effectiveness
2
Safety
Positron Emission Tomography
for Carcinoma
Rochester, MN
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Rochester, MN
18+
All Sexes
This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on the surface of liver cancer cells. The radioactive chemical compound (68Ga-PSMA) has been designed to circulate through the body and attach itself to the PSMA protein on liver cancer cells. A PET scan is then used to detect the location of the tumor cells. 68Ga-PSMA PET may improve upon the diagnosis and management of liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Pegargiminase
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 2
Recruiting
Houston, TX
18+
All Sexes
This study is evaluating whether a drug called nivolumab and a drug called ADI-PEG 20 can help control liver cancer before surgery.
Phase-Based Estimates
1
Effectiveness
2
Safety
Futibatinib
for Carcinoma, Hepatocellular
Rochester, MN
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Rochester, MN
18+
All Sexes
This study is evaluating whether futibatinib and pembrolizumab are safe and effective in treating patients with FGF19 positive liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Proton Stereotactic Body Radiation Therapy
for Carcinoma, Hepatocellular
Rochester, MN
18+
All Sexes
Phase 2
Recruiting
Grade III
Rochester, MN
18+
All Sexes
This study is evaluating whether stereotactic body proton radiotherapy is effective in treating patients with liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Atezolizumab
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 2
Recruiting
Houston, TX
18+
All Sexes
This study is evaluating whether a combination of two immunotherapy drugs may help prevent liver cancer from returning after surgery.
Phase-Based Estimates
1
Effectiveness
2
Safety
Pembrolizumab
for Carcinoma, Hepatocellular
Boston, MA
18+
All Sexes
Phase 2
Waitlist Available
Locally Advanced
Boston, MA
18+
All Sexes
Researchers are looking for a better way to treat people suffering from liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment (advanced metastatic hepatocellular carcinoma, HCC). Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers will learn more about the trial treatment, regorafenib, in a small number of participants. They will study the results when the trial treatment is taken with another cancer treatment called pembrolizumab. There will be 2 parts to this trial. The part 1 (pilot phase) will include about 52 men and women. The part 2 (expansion phase) will include about 67 men and women. All of the participants will have HCC and will be aged 18 years or older. All of the participants will have tried other treatments that did not help their HCC. These other treatments (PD-1/PD-L1 Immune Checkpoint Inhibitors) are designed to work by stopping the activity of certain proteins in the immune system thought to play a role in HCC. During both parts of the trial, the participants will take regorafenib and receive pembrolizumab. In the pilot phase, there will be 2 groups of participants. The group that each participant joins will be based on the treatment they already received for their HCC. The researchers will review the results in each group to learn if regorafenib and pembrolizumab are helping one group of participants more than others. Outcome of this review will determine the population to be treated in the expansion phase.
Phase-Based Estimates
1
Effectiveness
1
Safety
Durvalumab
for Carcinoma, Hepatocellular
Duarte, CA
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Duarte, CA
18+
All Sexes
This study is evaluating whether the combination of durvalumab and tremelimumab is safe and effective in treating patients with liver cancer that cannot be removed by surgery (unresectable) and has spread to nearby tissues and lymph nodes (loc
Phase-Based Estimates
1
Effectiveness
1
Safety
LIVE-R Life Education
for Liver Cancer
Philadelphia, PA
18+
All Sexes
Recruiting
Philadelphia, PA
18+
All Sexes
This study is evaluating whether an educational intervention can help reduce liver cancer rates in Philadelphia.
Phase-Based Estimates
1
Effectiveness
2
Safety
Cabozantinib
for Relapse
Toronto, Canada
18+
All Sexes
Phase 2
Recruiting
Grade I
Toronto, Canada
18+
All Sexes
This study is evaluating whether cabozantinib is useful in controlling the disease of patients who have had a liver transplant for liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Defined Green Tea Catechin Extract
for Fibrosis
Washington, United States
18+
All Sexes
Phase 1
Waitlist Available
Washington, United States
18+
All Sexes
This study is evaluating whether a specific type of green tea may help prevent liver cancer in patients with cirrhosis.
Phase-Based Estimates
1
Effectiveness
2
Safety
Ipilimumab
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 2
Waitlist Available
Houston, TX
18+
All Sexes
This study is evaluating whether nivolumab with or without ipilimumab is safe and effective in treating patients with liver cancer that can be removed by surgery.
Phase-Based Estimates
1
Effectiveness
1
Safety
Pembrolizumab
for Carcinoma, Hepatocellular
Buffalo, NY
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Buffalo, NY
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Simvastatin
for Liver Cirrhosis
Washington, United States
18+
All Sexes
Phase 2
Waitlist Available
Washington, United States
18+
All Sexes
This study is evaluating whether a common cholesterol medication may help prevent liver cancer in patients with liver cirrhosis.
Phase-Based Estimates
1
Effectiveness
2
Safety
Pembrolizumab
for Carcinoma
Houston, TX
18+
All Sexes
Phase 2
Waitlist Available
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether a combination of drugs may be more effective than a single drug in treating patients with liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Stereotactic Body Radiation Therapy
for Carcinoma, Hepatocellular
Palo Alto, CA
18+
All Sexes
Phase 3
Waitlist Available
1 Prior Treatment
Palo Alto, CA
18+
All Sexes
This study is evaluating whether a treatment called transarterial chemoembolization (TACE) is more effective than other treatments for liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Carbon C 11 Acetate
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 1
Recruiting
Metastatic
Houston, TX
18+
All Sexes
This study is evaluating whether a PET scan can help find and diagnose liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Erlotinib Hydrochloride
for Carcinoma, Hepatocellular
Jacksonville, FL
18+
All Sexes
Phase 1 & 2
Waitlist Available
Jacksonville, FL
18+
All Sexes
This study is evaluating whether a drug called erlotinib hydrochloride can help prevent liver cancer in patients with cirrhosis of the liver.
Phase-Based Estimates
1
Effectiveness
1
Safety
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
for Carcinoma, Hepatocellular
Scottsdale, AZ
18+
All Sexes
Phase 1
Waitlist Available
Locally Advanced
Scottsdale, AZ
18+
All Sexes
This study is evaluating whether a virus can be used to deliver interferon beta to patients with liver cancer or solid tumors.
Phase-Based Estimates
1
Effectiveness
1
Safety
TheraSphere
for Carcinoma
Philadelphia, PA
18+
All Sexes
Waitlist Available
Philadelphia, PA
18+
All Sexes
This study is evaluating whether a drug called TheraSphere can improve the survival of people with liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Doxorubicin Hydrochloride
for Carcinoma, Hepatocellular
Decatur, GA
18+
All Sexes
Phase 3
Waitlist Available
Class II
Decatur, GA
18+
All Sexes
This study is evaluating whether a combination of sorafenib and doxorubicin hydrochloride is more effective than sorafenib alone in treating patients with liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Temsirolimus
for Hepatoblastoma
Kansas City, MO
< 65
All Sexes
Phase 3
Waitlist Available
Metastatic
Kansas City, MO
< 65
All Sexes
This study is evaluating whether a risk-based treatment plan is better than a standard treatment plan for treating younger patients with newly diagnosed liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Immunologic Technique
for Liver Neoplasms
New York, NY
18+
All Sexes
Phase 2
Waitlist Available
Class II
New York, NY
18+
All Sexes
This study is evaluating whether a combination of chemotherapy and bevacizumab is more effective than chemotherapy alone in treating people with liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Social Support Network Intervention
for Carcinoma, Renal Cell
Tucson, AZ
18+
All Sexes
Waitlist Available
Tucson, AZ
18+
All Sexes
This project will develop and pilot test social support intervention for an underserved population, Hispanics in Arizona, who have high rates of kidney and liver cancer to improve health equity. The investigators will incorporate caregivers (family members) and other individuals in a patient's social network in survivorship, who are especially critical to quality cancer care. Caregivers provide more than half the care to cancer survivors and are often instrumental in facilitating the survivor to receive the care needed and adhere to guidelines. Through this project, the investigators will be able to leverage the resources of the Cancer Heath Equity Research Center (e.g., community outreach) to develop an intervention that has the potential for scalability and reach and recruit a sufficient sample across the target catchment area (including rural participants who may live near the US-Mexico border).
Phase-Based Estimates
1
Effectiveness
1
Safety
Biopsy
for Hepatocellular Carcinoma
Atlanta, GA
18+
All Sexes
Phase < 1
Recruiting
Metastatic
Atlanta, GA
18+
All Sexes
This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites (oligometastatic). Radioembolization with Y90 is a minimally invasive procedure that combines embolization and radiation therapy to treat metastatic liver cancer. Tiny beads filled with radioactive isotope Y-90 are placed inside the blood vessel that provide blood supply to the tumor. This will block the blood flow to the tumor cells while providing a high radiation dose without harming healthy normal tissue.
Phase-Based Estimates
1
Effectiveness
2
Safety
Atezolizumab
for Carcinoma
Urbana, IL
18+
All Sexes
Phase 2
Recruiting
Class II
Urbana, IL
18+
All Sexes
This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy alone in treating patients with liver cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bevacizumab and atezolizumab with chemotherapy may kill more tumor cells in patients liver cancer than chemotherapy alone.
Phase-Based Estimates
1
Effectiveness
1
Safety
Control Group
for Liver Diseases
Houston, TX
18+
All Sexes
Recruiting
Houston, TX
18+
All Sexes
To determine the effectiveness of a behaviorally-based tailored disease management intervention in patients with fibrosis or steatosis and risk factors for cirrhosis.
Phase-Based Estimates
1
Effectiveness